PIRS Pieris Pharma: Enterprise Value to EBITDA Ratio
Prospects for revising the cost of clinical projects are already taking shape, and resource-saving measures have been priced in by the market. Pieris Pharmaceuticals (PIRS) is based in the US and Germany, developing protein-based oncology treatments through alliances with industry behemoths. This price chart featuring the 0.00 indicator confirms the potential of the anticalin platform, which replaces standard antibodies and creates robust intellectual property protection.
Comprehensive metric breakdowns and analytics for pieris.com (PIRS)
- market price and analyst price targets:
- company stock capitalization data:
- business book valuation details:
- debt obligations and liquidity statistics:
Debt to Equity Pieris Pharmaceuticals|PIRS - Long-Term Debt to Capital Coefficient|Short-Term Debt to Equity Pieris Pharmaceuticals, Inc.|PIRS - Company Aggregate Indebtedness|Debts to Book Capitalization Pieris Pharma|PIRS - Long-Term Debt Volume|Company Short-Term Debts Pieris Pharmaceuticals|Quick Liquidity pieris.com
- financial results and valuation multiples details:
PIRS - Final Profit|Projected Future Earnings Pieris Pharmaceuticals|PIRS - Business Payback Period|Future Price to Earnings Pieris Pharmaceuticals|PIRS - Growth-Adjusted Market Cap to Net Income|Enterprise Value to EBITDA Ratio Pieris Pharma|PIRS - Income before deduction of interest, taxes and amortization|Earnings per share for the last twelve months Pieris Pharmaceuticals|PIRS - Earnings per one share for the last 12 months|Quarterly EPS earnings growth pieris.com|PIRS - Earnings per share increase in current year|Earnings growth forecast for next year Pieris Pharmaceuticals
Fundamental valuation:Pieris PIRS
To objectively assess the fundamental quality of Pieris Pharmaceuticals (PIRS), an investor must analyze the total business value relative to its operating cash flow. This metric compares the enterprise value, including debt, against earnings before interest, taxes, depreciation, and amortization, revealing hidden credit risks. The EV/EBITDA ratio trend, accounting for operating profit and depreciation, confirms the effectiveness of investments in bioinformatic AI and laboratory robotics.
Analysis of competing companies
Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Haleon Group HLN|Kenvue Health (KVUE) - Company Value to EBITDA|VRNA: Enterprise Value to EBITDA Ratio|jyongbio.com - Enterprise Value to Operating Income Before Depreciation Ratio|LGND: EV/EBITDA Multiple|Amneal Pharmaceuticals, Inc. - Business Value to Operating Income Before Depreciation|PRGO (Perrigo Company) - EV/EBITDA Multiple|Company Value to EBITDA Alvotech Biopharmaceuticals ALVO|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Liquidia Corporation (LQDA)|GLPG (glpg.com) - Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization ANI Pharmaceuticals, Inc. ANIP|MNKD (MannKind Corp) - Company Value to Operating Income Before Depreciation Ratio|Amphastar - EV/EBITDA Multiple|Total Company Value to Operating Income Before Depreciation Ratio Pacira Corp PCRX|SPRY: EV/EBITDA Multiple|Company Value to EBITDA theravance.com (TBPH)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Aquestive Therapeutics, Inc.|SCPH: Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple TECX|Total Company Value to Operating Income Before Depreciation Ratio Tonix Pharmaceuticals Holding|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization China SXT Pharmaceuticals, Inc. SXTC|Total Company Value to Operating Income Before Depreciation Ratio Eupraxia Pharmaceuticals, Inc. (EPRX)|BHST: Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation EXOZ (Invizyne Technologies)|oramed.com (ORMP) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to Operating Income Before Depreciation Ratio ENTX (Entera Bio)|HYFT (MindWalk Holdings) - EV/EBITDA Multiple|ABVC: Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple CPIX|EV/EBITDA Multiple Quantum BioPharma Ltd. (QNTM)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization FibroGen Corp FGEN|Business Value to Operating Income Before Depreciation TELO|RANI - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Synergy CHC Corp (SNYR) - Enterprise Value to EBITDA Ratio|RLYB: EV/EBITDA Multiple|Lexaria Bioscience Corp. (LEXX) - EV/EBITDA Multiple|PULM (Pulmatrix Corp) - EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio Pheton (PTHL)|EV/EBITDA Multiple APM|LYRA - Company Value to EBITDA|Impact BioMedical - Enterprise Value to EBITDA Ratio|EV/EBITDA Multiple TNF Pharmaceuticals Inc. TNFA|YCBD: Enterprise Value to EBITDA Ratio|PainReform Corp - Enterprise Value to Operating Income Before Depreciation Ratio|CYTO: EV/EBITDA Multiple|LIPO - Total Company Value to Operating Income Before Depreciation Ratio|OPTN (OptiNose) - EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio Procaps Group (PROC)|EV/EBITDA Multiple PTPI|EV/EBITDA Multiple Qilian International Corp (QLI)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Acelyrin, Inc. SLRN|tffpharma.com - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization
